RBC Capital analyst Sean Dodge maintained a Buy rating on Tabula Rasa HealthCare (NASDAQ:TRHC) on Sunday, setting a price target of $70, which is approximately 37.07% above the present share price of $51.07.
Dodge expects Tabula Rasa HealthCare to post earnings per share (EPS) of -$0.85 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Tabula Rasa HealthCare, with an average price target of $52.8.
The analysts price targets range from a high of $70 to a low of $45.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $76.68 million and a net profit of -$16.75 million. The company's market cap is $1.27 billion.
According to TipRanks.com, RBC Capital analyst Sean Dodge is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.1% and a 57.14% success rate.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.